Treatment AI (CSE: TRUE) Unveils New AI-Powered Solutions Revolutionizing Medical Education

Treatment AI (CSE: TRUE) Unveils New AI-Powered Solutions Revolutionizing Medical Education
HEALWELL AI Inc (TSX: AIDX), HEALWELL AI Inc (OTCQX: HWAIF), Exscientia PLC (NASDAQ: EXAI), Certara Inc. (NASDAQ: CERT), Relay Therapeutics Inc. (NASDAQ: RLAY), BioXcel Therapeutics Inc. (NASDAQ: BTAI), Royalty Pharma PLC (NASDAQ: RPRX), Alphabet Inc. (NASDAQ: GOOGL), Amazon.com Inc. (NASDAQ: AMZN), International Business Machines Corp. (NYSE: IBM), GE HealthCare Technologies Inc. (NASDAQ: GEHC), VERSES AI Inc (OTCMKTS: VRSSF), VERSES AI Inc (CBOE: VERS)

The global artificial intelligence (AI) in healthcare market size was estimated at USD 15.1 billion in 2022 and it is expected to surpass around USD 187.95 billion by 2030, growing at a CAGR of 37% during the forecast period 2022 to 2030. North America AI in healthcare market was valued at USD 6.8 billion in 2022. This suggests that companies with a viable healthcare-related AI product could benefit from the growing use of AI in healthcare. In a groundbreaking advancement for medical education, Treatment AI (CSE: TRUE) has introduced two innovative solutions: AI Patient and AI Doctor in a Pocket. These additions are set to revolutionize the way healthcare professionals and students learn and practice, reinforcing Treatment’s commitment to harnessing artificial intelligence to transform medical education. Treatment AI (CSE: TRUE) is currently trading at CAD 0.7300, up +0.0300 (+4.2857%) on Wednesday. As the medical AI sector heats up, there could be significant upside potential for this micro-cap company.

Bridging Gaps in Medical Training with AI

The new solutions are part of Treatment’s Medical Education Suite (MES), which is meticulously designed to span the entire continuum of clinical content education. From basic patient interactions to advanced diagnostic evaluations and faculty benchmarking, the MES reduces administrative costs and enhances learning outcomes.

The AI Patient and AI Doctor in a Pocket are both subscription-based SaaS offerings that integrate seamlessly with the existing suite. Their launch, scheduled for the second half of 2024, is highly anticipated among healthcare communities in the United States, Canada, and the United Kingdom.

AI Patient: A New Standard for Exam Preparation

AI Patient utilizes a comprehensive AI and a robust library of test cases to assist students in preparing for multiple-choice questions (MCQs) and Objective Structured Clinical Examinations (OSCE). By simulating real-life scenarios, it provides a dynamic platform for students to hone their diagnostic skills and readiness for these crucial exams, which are utilized in 57 countries to assess the practical reasoning skills of healthcare professional students.

AI Doctor in a Pocket: Expertise at Your Fingertips

On the other hand, AI Doctor in a Pocket offers a mobile-friendly AI-powered clinical decision support tool that is invaluable for healthcare professionals and students in clinical settings. This tool provides immediate access to expert guidance and decision-making support, which is critical when working in fast-paced environments such as clinics and hospital wards.

Backed by the Global Library of Medicine

Both new solutions leverage Treatment’s proprietary Global Library of Medicine (GLM), an extensive and integrated online medical library developed with the input of hundreds of credentialed clinicians worldwide. The GLM ensures that users receive only the highest quality clinical information, which translates to improved accuracy and efficiency in medical practice and education.

Commitment to Next-Generation Healthcare Professionals

Dr. Essam Hamza, CEO of Treatment.com AI Inc. (CSE: TRUE) (OTC: TREIF), expressed his enthusiasm about the expansion of their solutions, emphasizing their strategic focus on supporting and advancing the education of the next generation of clinicians. “Our goal is for students to be supported and excel during their medical education and to continue utilizing our trusted platform as they transition into practice,” Dr. Hamza stated. Moreover, Treatment.com AI is not just about enhancing educational tools; it also aims to foster health equity and inclusion for underserved communities through its innovations. This vision is underpinned by the company’s long-standing commitment to using AI for good, providing a testament to the transformative potential of AI in healthcare.

Looking Ahead

With these developments, Treatment.com AI continues to pave the way for a future where AI not only augments medical education but also enhances the overall efficiency and effectiveness of healthcare delivery. As these tools are rolled out, they promise to empower a new era of healthcare professionals equipped with knowledge and tools that are at the cutting edge of technology and patient care.

In another development, HEALWELL AI Inc (TSX: AIDX) (OTCQX: HWAIF), a healthcare technology company focused on AI and data science for preventative care, announced that its subsidiaries Khure Health Inc. (“Khure”) and Pentavere Research Group Inc. (“Pentavere”) will be presenting their breakthrough AI work at the following medical conferences in May 2024. Don Watts, President of Khure, will be participating in the following upcoming medical conference, where Khure’s AI-enabled clinical decision support technology is featured in a presentation showing its utility in supporting US Nephrologists with guideline directed patient care in Chronic Kidney Disease. Healthcare AI related stocks to keep an eye on include Exscientia PLC (NASDAQ: EXAI), Certara Inc. (NASDAQ: CERT), Relay Therapeutics Inc. (NASDAQ: RLAY), BioXcel Therapeutics Inc. (NASDAQ: BTAI), Royalty Pharma PLC (NASDAQ: RPRX), Alphabet Inc. (NASDAQ: GOOGL), Amazon.com Inc. (NASDAQ: AMZN), International Business Machines Corp. (NYSE: IBM), GE HealthCare Technologies Inc.’s (NASDAQ: GEHC) and VERSES AI Inc (OTCMKTS: VRSSF) (CBOE:VERS)

 

Disclaimer: This news article is for information purposes only and is neither a solicitation or recommendation to buy nor an offer to sell securities. The Bull Report is not-a-registered-investment-advisor. The Bull Report is not a broker-dealer. Information, opinions, and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. The Bull Report accepts no liability for any losses arising from an investor’s reliance on the use of this material. Starting on Mar 15, 2024 The Bull Report has been compensated $47,000 per month for coverage of TRUE by Sunburst Capital Corp. The Bull Report and its affiliates or officers may purchase, hold, and sell shares of common stock of this stock, in the open market at any time without notice. The Bull Report will not update its purchases and sales of this stock in any future postings on The Bull Report’s websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words “may”, “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend,” ” project,” and similar expressions and variations thereof are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *The Bull Report does not set price targets on securities. Never invest in a stock discussed on this website or in this email alert unless you can afford to lose your entire investment.

Sources: 

https://finance.yahoo.com/news/treatment-com-ai-welcomes-federal-120000957.html

https://www.cbc.ca/news/politics/federal-government-ai-investment-1.7166234

https://finance.yahoo.com/news/treatment-com-ai-funded-national-120000374.html

https://ca.finance.yahoo.com/news/healwell-ai-pentavere-achieves-validation-110000955.html

https://finance.yahoo.com/quote/TRUE.CN/

https://finance.yahoo.com/news/repeat-treatment-com-ai-announces-120000231.html

https://www.precedenceresearch.com/artificial-intelligence-in-healthcare-market#:~:text=The%20global%20artificial%20intelligence%20(AI,forecast%20period%202022%20to%202030.

Media Contact
Company Name: TheBullReport
Contact Person: Jason Roy
Email: [email protected]
City: Dallas
State: Texas
Country: United States
Website: https://www.thebullreport.com/


Posted

in

by

Tags: